1.62
-0.02(-1.22%)
Currency In USD
| Previous Close | 1.64 |
| Open | 1.72 |
| Day High | 1.72 |
| Day Low | 1.55 |
| 52-Week High | 4.92 |
| 52-Week Low | 0.87 |
| Volume | 400,150 |
| Average Volume | 488,870 |
| Market Cap | 79.34M |
| PE | -0.84 |
| EPS | -1.94 |
| Moving Average 50 Days | 1.75 |
| Moving Average 200 Days | 1.91 |
| Change | -0.02 |
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
GlobeNewswire Inc.
Jun 23, 2025 11:40 AM GMT
12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure Median weight remained stable through 3 months (0.46% / ~ 1 pound weight change within the
Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
GlobeNewswire Inc.
Jun 23, 2025 11:30 AM GMT
New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity Rejuva-treated healthy animals exposed to a high fat diet were protected from weight gain and hyperglycemia Data reinforce adv
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
GlobeNewswire Inc.
Jun 18, 2025 11:00 AM GMT
Robust intellectual property portfolio, built over more than a decade, designed to protect core innovations for treating metabolic diseases New U.S. patents strengthen Fractyl’s leadership in metabolic innovation by expanding its patent coverage of d